Advances in the treatment of precocious puberty

Bibliography

• PESCOVITZ OH: Precocious puberty. Pediatr. Rev (1990) 11:229–237.
   PubMedGoogle Scholar
• HERMAN-GIDDENS ME, SLORA EJ, WASSERMAN RC et al: Secondary sexual characteristics and menses in young girls seen in office practice: a study from the pediatric research in office settings network. Pediatrics. (1997) 99:505–512.
   PubMed Web of Science ®Google Scholar
• EUGSTER EA, PESCOVITZ OH: Precocious puberty. In: Endocrinology 4th Ed. DeGroot LJ, Jameson JL (Eds.), W.B. Saunders Company, Philadelphia, USA (2001):2011–2021.
   Google Scholar
• TANG M, FENTON C, POTH M: Review of Precocious Puberty Part II: Gonadotropin-Independent Precocious Puberty. The Endocrinologist (2000) 10:397–402.
   Web of Science ®Google Scholar
• CROWLEY WE COMITE E VALE W etal.: Therapeutic use of pituitary desensitization with a long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. I Clin. Endocrine]. Metab. (1981) 52:370–372.
   PubMed Web of Science ®Google Scholar
• •Initial report of long-acting GnRH analogue therapy for precocious puberty.
   Google Scholar
• PESCOVITZ OH, COMITE F, HENCH K et al.: The NIH experience in precocious puberty: diagnostic subgroups and the response to short-term LHRH analogue therapy. I Pediatr. (1986) 108:47–54.
   Web of Science ®Google Scholar
• ARRIGO T, CISTERNINO M, GALLUZZI F etal.: Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur. Endocnirol. (1999) 141:140–144.
   Google Scholar
• BERTELLONI S, BARONCELLI GI, FERDEGHINI M, MENCHINI-FABRIS SAGGESE G: Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur. I Pediatr. (2000) 159(5):369–374.
   PubMed Web of Science ®Google Scholar
• HEGER S, PARTSCH CJ, SIPPELL WG: Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. j Clin. Endocrirrol. Metab. (1999) 84(12):4583–4590.
   PubMed Web of Science ®Google Scholar
• BOEK JENSEN AM, BROCKS V, HOLM K, LAURSEN EM, MOLLER J: Central precocious puberty in girls: Internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues. I Pediatr. (1998) 132:105–108.
   Web of Science ®Google Scholar
• PASQUINO AM, PUCARELLI I, SEGNI M, MATRUNOLA M, CERRONE F: Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. Endocnirol. Metab. (1999) 84:449–452.
   PubMed Web of Science ®Google Scholar
• PESCOVITZ OH, CASSORLA F, COMITE F, LORIAUX DL, CUTLER GB JR.: LHRH Analog treatment of central precocious puberty complicating congenital adrenal hyperplasia. Ann. NY Acad. Sci (1985) 458:174–181.
   Google Scholar
• •A report describing the novel application of an LHRH analogue in the setting of secondary central precocious puberty.
   Google Scholar
• SAGGESE G, CESARETTI G, BARSANTI S, ROSSI A: Combination treatment with growth hormone and gonadotropin-releasing hormone analogs in short normal girls. I Pediatr. (1995) 126:468–473.
   Web of Science ®Google Scholar
• SAGGESE G, FEDERICO G, BARSANTI S, FIORE L: The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study. I Clin. Endocrirrol. Metab. (2001) 86(5):1900–1904.
   PubMed Web of Science ®Google Scholar
• BREYER P, HAIDER A, PESCOVITZ OH: Gonadotropin-releasing hormone agonists in the treatment of girls with precocious puberty. Clin. Obstet. Cyr]. (1993) 36(3):764–772.
   PubMed Web of Science ®Google Scholar
• ALBANO C, FELBERBAUM RE, SMITZ J et al.: Ovarian stimulation with HMG: results of a prospective randomized Phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum. Reprod. (2000) 15(3):526–531.
   PubMed Web of Science ®Google Scholar
• LUBIN V, CHARBONNEL B, BOUCHARD P: The use of gonadotropin-releasing hormone antagonists in polycystic ovarian disease. Ball.Clin. Obstet. Cyrrecol. (1998) 12(4):607–618.
   PubMed Web of Science ®Google Scholar
• ROTH C, LEONHARDT S, DEIDEL C, LUFT H, WUTTKE W, JARRY H: Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model. PedMtr. Res. (2000) 48(4):468–474.
   PubMed Web of Science ®Google Scholar
• ••Preliminary data in an animal modelcomparing the differential effects of a GnRH analogue with a GnRH antagonist in the suppression of puberty.
   Google Scholar
• ERB K, PECHSTEIN B, SCHUELER A, ENGEL J, HERMANN R: Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverilix in healthy men-a first-dose-in-humans study. Clin. Pharm. net: (2000) 67(6):660–669.
   Web of Science ®Google Scholar
• LESCHEK EW, CUTLER GB, JR.: Familial male precocious puberty. Curr. Ther. Endocrirrol. Metab. (1997) 6:343–345.
   PubMedGoogle Scholar
• SHENKER A, LAUE L, KOSUGI S et al.: A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature (1993) 365:652–654.
   PubMed Web of Science ®Google Scholar
• •Elucidation of the molecular basis for familial male precocious puberty.
   Google Scholar
• GROMOLL J, PARTSCH C-J, SIMONI M et al.: A mutation in the first transmembrane domain of the lutropin receptor causes male precocious puberty. Endocrirrol. Metab. (1998) 83(2):476–480.
   PubMed Web of Science ®Google Scholar
• KRAAIJ R, POST M, KREMER H et al.: Amissense mutation in the second transmembrane segment of the luteinizing hormone receptor causes familial male-limited precocious puberty. I Clin. Eric/or/Mal Metab. (1995) 80(11):3168–3172.
   PubMed Web of Science ®Google Scholar
• LATRONICO AC, ABELL AN, ARHNOLD JP etal.: A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. I Clin. Endocrirrol. Metab. (1998) 83:2435–2440.
   Google Scholar
• LAUE L, CHAN W-Y, HSUEH AJW et al.:Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male precocious puberty. Proc. Nati Acad. Sci. USA (1995) 92:1906–1910.
   PubMed Web of Science ®Google Scholar
• KREMER H, MARTENS JWM, REEN M VAN et al.: A limited repertoire of mutations of the luteinizing hormone receptor gene in familial and sporadic patients with male LH-independent precocious puberty. I Clin. Endocrirrol. Metab. (1999) 84:1136–1140.
   Google Scholar
• ROSENTHAL SM, GRUMBACH MM, KAPLAN SL: Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testitoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. I Clin. Endocnirol. Metab. (1983) 57:571–579.
   PubMed Web of Science ®Google Scholar
• HOLLAND FJ, FISHMAN L, BAILEY JD, FAZEKAS ATA: Ketoconizole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Ere. J Med. (1989) 312:1023–1028.
   Web of Science ®Google Scholar
• BABOVIC-VUKSANOVIC D, DONALDSON MDC, GIBSON NA, WALLACE AM: Hazards of ketoconazole therapy in testitoxicosis. Acta. Paediatr. (1994) 83:994–997.
   PubMed Web of Science ®Google Scholar
• HOLLAND FJ: Gonadotropin-independent precocious puberty. Endocnirol. Metab. Cliii. North Am. (1991) 20:191–210.
   PubMed Web of Science ®Google Scholar
• BERTELLONI S, BARONCELLI GI, LALA R, CAPPA M et al.: Long-term outcome of male-limited gonadotropin-independent precocious puberty. Harm Res. (1997) 48(5):235–239.
   PubMed Web of Science ®Google Scholar
• SMITH EP, BOYD J, FRANK GR et al.:Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Ere. J Med. (1994) 331:1056–1061.
   PubMed Web of Science ®Google Scholar
• •First discovery of an oestrogen receptor mutation in man.
   Google Scholar
• MORISHIMA A, GRUMBACH MM, SIMPSON ER, FISHER C, QIN K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. 1. CM]. Eridocnirol Metall. (1995) 80:3689–3698.
   Google Scholar
• CARANI C, QIN K, SIMONI M et al: Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl. 1. Med. (1997) 337:91–95.
   PubMed Web of Science ®Google Scholar
• LAUE L, JONES J, BARNES KM, CUTLER GB, JR.: Treatment of familial male precocious puberty with spironolactone, testolactone and deslorelin. 1. Chi]. Eric/on-ilia Metab. (1993) 76:151–155.
   Google Scholar
• LESCHEK E, JONES J, BARNES KM, HILL SC, CUTLER GB: Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. I Chi]. Eridocrinol Metab. (1999) 84:175–178.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN LS, SHENKER A, GEJMAN PV, MERINO MJ, FRIEDMAN E, SPIEGEL AM: Activating mutations of the stimulatory G protein in the McCune-Albright Syndrome. N Engl. 1. Med. (1991) 325:1688–1738.
   PubMed Web of Science ®Google Scholar
• •Description of the underlying molecular basis for McCune-Albright Syndrome.
   Google Scholar
• COLLINS MT, SHENKER A: McCune-Albright Syndrome. Cun: Opiri. Eridocrinol Diabetol. (1999) 6:119–125.
   Google Scholar
• SHENKER A, WEINSTEIN LS, MORAN A et al: Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein Gs. 1. Pediatr: (1993) 123:509–518.
   Google Scholar
• FOSTER CM, FEUILLAN E PADMANABHAN V et al: Ovarian function in girls with McCune-Albright syndrome. Pediatr. Res. (1986) 20(9):859–863.
   PubMed Web of Science ®Google Scholar
• ESCOBAR ME, GRYNGARTEN M, DOMENE H, ROPELATO G, LOPEZ MR, BERGADA C: Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome. 1. Pediatr: (1997) 10:147–151.
   Google Scholar
• FEUILLAN PP: McCune-Albright Syndrome. Cun: Ther. Eridocrinol (1997) 6:235–239.
   Google Scholar
• FEUILLAN PP, JONES J, CUTLER GB: Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright Syndrome. 1. CM]. Eridocnirol Metab. (1993) 77(3):647–651.
   Google Scholar
• TAYLOR PD, HOWELL A: The therapeutic potential of novel aromatase inhibitors in breast cancer. Expert Opiri. Investig. Drugs. (1999) 8(3):269–279.
   PubMedGoogle Scholar
• FEUILLAN P, MERKE D, LESCHEK EW, CUTLER GB JR.: Use of aromatase inhibitors in precocious puberty. Eridocr. Relat. Cancer (1999) 6(2):303–306.
   Google Scholar
• •A review of the use of aromatase inhibitors in the treatment of precocious puberty.
   Google Scholar
• MAURAS N, O'BRIEN K, KLEIN KO, HAYES V: Estrogen suppression in males: metabolic effects. j. Chi]. Eric/on-ilia Metab. (2000) 85(7):2370–2377.
   PubMed Web of Science ®Google Scholar
• WICKMAN S, SIPILA I, ANKARBERG-LINDGREN C, NORJAVAARA E, DUNKEL L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet (2001) 357:1743–1748.
   PubMed Web of Science ®Google Scholar
• ••Initial investigation of the metaboliceffects of a novel aromatase inhibitor in children.
   Google Scholar
• GRUMBACH MM, AUCHUS RJ: Estrogen: consequences and implications of human mutations in synthesis and action. I Chi]. Eridocrinol Metab. (1999) 84:4677–4694.
   PubMed Web of Science ®Google Scholar
• NUNEZ SB, FEUILLAN PP, JONES J, CUTLER GB JR: The aromatase inhibitor fadrozole is not an effective treatment for the precocious puberty in the McCune-Albright syndrome. Program and Abstracts, Endocrine Society 79th Annual Meeting (1997) 413:(Abstract)
   Google Scholar
• EUGSTER EA, SHANKAR R, FEEZLE LK, PESCOVITZ OH: Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome. (1999)1 Pediatr. Eridocrinol Metall. 12: 681–686.
   Google Scholar
• •Case report of successful treatment of precocious puberty in McCune-Albright syndrome with tamoxifen.
   Google Scholar
• RODENS K, MULLER M, TELLER WM: Clinical, hormonal and sonographical characteristics of remission during treatment of pseudoprecocious puberty in the McCune-Albright syndrome. (1989) Acta Eridocrinol 120(1):172–173 (Abstract 186).
   Google Scholar
• DI MARTINO-NARDI J: Safety and efficacy of tamoxifen therapy in a two year old girl with McCune-Albright syndrome. (2000) The Endo Society 522:56 (Abstract 21).
   Google Scholar
• KONIG R, SCHONBERGER W, NEUMANN P, BENES P, GRIMM W: Treatment of marked gynecomastia in puberty with tamoxifen. Klinische Padiatrie (1987) 199(6):389–391.
   PubMed Web of Science ®Google Scholar
• FISHER B, CONSTANTINO JP, REDMOND CK et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. _J. Natl. Cancer Inst. (1994) 86:527–537.
   PubMed Web of Science ®Google Scholar
• OSBORNE CK: Tamoxifen in the treatment of breast cancer. N Engl. I. Med. (1998) 339(22):1609–1617.
   PubMed Web of Science ®Google Scholar
• SCANLON EF, BURKETT FE, SENER SF et al: Breast carcinoma in an 11 year old girl with Albright's syndrome. (1998) Breast 6(1):6–9.
   Google Scholar
• GUNTHER DF, CALIKOGLU AS, UNDERWOOD LE: The effects of the estrogen receptor blocker Faslodex 182,780), on estrogen-Accelerated bone maturation in Mice. (1999) Pediatr: Res. 46: 269–273.
   Google Scholar
• ••Early evidence that Faslodex can blockoestrogen-mediated skeletal maturation in mice.
   Google Scholar
• HOWELL A, OSBORNE CK, MORRIS C, WAKELING AE: ICI 182,780 (Faslodex): development of a novel, 'pure' antiestrogen. (2000) Cancer 89 (4):817–825.
   Google Scholar
• SINGH SM, GAUTHIER S, LABRIE F:Androgen receptor antagonists (antiandrogens): structure-activity relationships. (2000) Curr. Medic. Chem. 7(2):211–247.
   Google Scholar